Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +0.49%21 Return-on-Tangible-Equity is 70.77% as of Mar. 2026, which is 7% below its 10-year median of 76.50. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 899 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 92.21% on this metric.
The historical rank and industry rank for Sanofi Consumer Healthcare India's Return-on-Tangible-Equity or its related term are showing as below:
NSE:SANOFICONR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 73.39 Med: 76.5 Max: 85.02
Current: 85.02
During the past 3 years, Sanofi Consumer Healthcare India's highest Return-on-Tangible-Equity was 85.02%. The lowest was 73.39%. And the median was 76.50%.
NSE:SANOFICONR's Return-on-Tangible-Equity is ranked better than 92.21% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs NSE:SANOFICONR: 85.02
Sanofi Consumer Healthcare India (NSE:SANOFICONR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sanofi Consumer Healthcare India Return-on-Tangible-Equity Related Terms
Sanofi Consumer Healthcare India Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India Return-on-Tangible-Equity Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 70.77% mean?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Return-on-Tangible-Equity of 70.77% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sanofi Consumer Healthcare India and its competitors. This is near median its historical median of 76.50. Over the past decade, Sanofi Consumer Healthcare India's Return-on-Tangible-Equity has ranged from 73.39 to 85.02. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #70 out of 899 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Sanofi Consumer Healthcare India's Return-on-Tangible-Equity too high?
Sanofi Consumer Healthcare India's current Return-on-Tangible-Equity of 70.77% is near median its 10-year median of 76.50. Over the past 10 years, this metric has ranged from a low of 73.39 to a high of 85.02. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Sanofi Consumer Healthcare India's value of 70.77% is 790.2% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #70 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #70 out of 899 companies for Return-on-Tangible-Equity. This places Sanofi Consumer Healthcare India in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.95. Sanofi Consumer Healthcare India's value of 70.77% is 790.2% above this benchmark. Historically, Sanofi Consumer Healthcare India's own Return-on-Tangible-Equity has ranged from 73.39 to 85.02 over the past decade. While the company's 10-year median is 76.50 vs. the industry median of 7.95, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Return-on-Tangible-Equity of 70.77% is 790.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Return-on-Tangible-Equity is 70.77%, which is near median its own 10-year median of 76.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Return-on-Tangible-Equity of 70.77%. The current Return-on-Tangible-Equity is 70.77%, which is near median its 10-year median of 76.50 and 790.2% above the Drug Manufacturers industry median of 7.95. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Return-on-Tangible-Equity is 70.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Business Description
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
